公开(公告)号：US09480712B2

公开(公告)日：2016-11-01

申请号：US14514137

申请日：2014-10-14

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Ya-Chin Lo ,  Hsiang-Fa Liang ,  Ming-Cheng Wei ,  Maggie J. M. Lu ,  Min-Ying Lin ,  Chih-Peng Liu ,  Chun-Min Liu ,  Hsiang-Wen Tseng ,  Tse-Min Teng ,  Jui-Hsiang Chen ,  Yi-Man Chou ,  Yi-Ting Hsieh ,  Chia-Mu Tu

IPC: C08B37/08 ,  A61K47/48 ,  A61K31/704 ,  A61K31/4745 ,  A61K31/7036 ,  A61K33/24 ,  A61K45/06 ,  A61K31/4172 ,  A61K31/555 ,  A61K31/728

CPC classification number: A61K33/24 ,  A61K31/4172 ,  A61K31/4745 ,  A61K31/555 ,  A61K31/7036 ,  A61K31/704 ,  A61K31/728 ,  A61K45/06 ,  A61K47/542 ,  A61K47/61 ,  A61K47/6921 ,  A61K2300/00

Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.

Abstract translation: 本公开提供了一种生物医学组合物，其包括：透明质酸; 修饰的组氨酸 和聚合物或C 4 -C 20烷烃，其中将经修饰的组氨酸和聚合物或C 4 -C 20烷烃接枝至透明质酸的至少一个伯羟基，以使透明质酸形成透明质酸衍生物，其中接枝率 的改性组氨酸约为1-100％，聚合物或C4-C20烷烃的接枝率约为0-40％。

公开(公告)号：US09408917B2

公开(公告)日：2016-08-09

申请号：US13926363

申请日：2013-06-25

Applicant: Industrial Technology Research Institute

Inventor： Maggie J. M. Lu ,  Yu-Wen Lo ,  Chih-Peng Liu ,  Chia-Wen Huang ,  Shuen-Hsiang Chou ,  Po-Hung Lai ,  Tsan-Lin Hu ,  Min-Ying Lin ,  Chia-Mu Tu

IPC: A61K47/36 ,  A61K9/00 ,  A61K9/127

CPC classification number: A61K47/36 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/127

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract translation: 本公开提供药物组合物。 药物组合物包括具有棕榈酰基团的壳聚糖和活性剂。 根据另一个实施方案，药物组合物可以进一步包括胶凝加速剂。 根据本公开的实施方案，本公开的活性剂可以以纳米药物，脂质体，胶束或微粒的形式施用。

公开(公告)号：US09012459B2

公开(公告)日：2015-04-21

申请号：US13968089

申请日：2013-08-15

Applicant: Industrial Technology Research Institute

Inventor： Yen-Fang Wen ,  Yuan-Jang Tsai ,  Wan-Ru Chen ,  Tsan-Lin Hu ,  Chia-Mu Tu ,  Chih-Peng Liu

IPC: A61K31/4965 ,  C07D403/04

CPC classification number: C07D403/04

Abstract: The disclosure is directed to a monohydrate crystalline form of 3-(5-(4-(3-fluoropropyl)piperazin-1-yl)benzimidazol-2-yl)-1-azaazulen-2-one, possessing diffraction peaks of about 12.9°, 15.9°, 17.9°, 21.2°, 22.9°, 23.5° and 24.5°. Its preparation method and pharmaceutical composition thereof are also provided.

Abstract translation: 本发明涉及一水合物结晶形式的3-（5-（4-（3-氟丙基）哌嗪-1-基）苯并咪唑-2-基）-1-氮杂薁-2-酮，具有约12.9的衍射峰 °，15.9°，17.9°，21.2°，22.9°，23.5°和24.5°。 还提供了其制备方法和药物组合物。

公开(公告)号：US11608319B2

公开(公告)日：2023-03-21

申请号：US17117615

申请日：2020-12-10

Applicant: Industrial Technology Research Institute

Inventor： Chih-Wei Fu ,  Chih-Peng Liu ,  Yi-Hsun Chen ,  Chia-Mu Tu ,  Chiu-Lien Hung

IPC: C07D231/12 ,  C07D403/12 ,  A61P27/06

Abstract: A compound represented by Formula (I), a pharmaceutically acceptable salt or ester, hydrate, solvate or crystalline form thereof is provided: The compound represented by Formula (I) is a β-amino acid derivative, and in Formula (I) X is a single bond or O; Y is NH or C═O; Z is C═O, C═S, NH, W is C or N; A is a single bond, O, OH, OCH2, a heterocycle or N3; R1 is H or F; R2 is H, F, OH, CF3, CH2OH, CHO or R3 is H; n is 0 or 1; and m is 0 or 1.